Bevacizumab (International)
In the US, Bevacizumab (bevacizumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Breast Cancer, Breast Cancer - Metastatic, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme, Hepatocellular Carcinoma, Macular Degeneration, Malignant Glioma, Neurofibromatosis, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma and Solid Tumors.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01XC07
CAS registry number (Chemical Abstracts Service)
0216974-75-3
Chemical Formula
C6638-H10160-N1720-O2108-S44
Therapeutic Categories
Antineoplastic agent
Monoclonal antibody
Angiogenesis inhibitor
Vascular endothelial growth factor (VEGF) antagonist
Chemical Name
Immunoglobulin G1 (human-mouse monoclonal rhuMAb-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer (WHO )
Foreign Names
- Bevacizumabum (Latin)
- Bevacizumab (German)
- Bévacizumab (French)
- Bevacizumab (Spanish)
Generic Names
- Bevacizumab (OS: USAN)
- Bevacizumab (Genetical Recombination) (OS: JAN)
- anti-VEGF Mab (IS)
- Anti-VEGF monoclonal antibody (IS)
- rhuMAb-VEGF (IS)
- UNII-2S9ZZM9Q9V (IS)
- VEGF light chain, dimer (WHO) (IS)
Brand Names
- Altuzan Roche 100mg/4ml
Roche, Turkey - Altuzan Roche 400mg/16ml
Roche, Turkey - Avastin
Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche, Macedonia; Genentech, United States; Hoffmann-La Roche, Canada; Hoffmann-La Roche Ltd, Latvia; Productos Roche, Chile; Roche, Armenia; Roche, Argentina; Roche, Bosnia & Herzegowina; Roche, Belgium; Roche, Brazil; Roche, Colombia; Roche, Cyprus; Roche, Czech Republic; Roche, Denmark; Roche, Ecuador; Roche, Estonia; Roche, Egypt; Roche, Spain; Roche, Finland; Roche, Georgia; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Israel; Roche, Italy; Roche, Lebanon; Roche, Lithuania; Roche, Moldova; Roche, Myanmar; Roche, Mexico; Roche, Norway; Roche, New Zealand; Roche, Philippines; Roche, Poland; Roche, Portugal; Roche, Paraguay; Roche, Romania; Roche, Russian Federation; Roche, Sweden; Roche, Thailand; Roche, Taiwan; Roche, Vietnam; Roche, South Africa; Roche D.O.O., Serbia; Roche Farma, Peru; Roche Pharmaceutical, China; Roche Products, Australia; Roche Registration, Netherlands; Roche Registration Limited, Iceland; Roche Registration, Slovenia; Roche Uruguay, Uruguay - Avastin 100mg/4ml
Roche, Oman; Roche Pharma Schweiz, Switzerland - Avastin 25 mg/ml
Abacus, Austria; Haemato Pharm, Austria; Inopha, Austria; Orifarm, Austria; Roche, Germany; Roche, France; Roche, Hungary; Roche Products, United Kingdom; Roche Registration, Austria - Avastin 400mg/16ml
Roche, Oman; Roche Pharma Schweiz, Switzerland - Avastin Roche
Roche, Hong Kong - Avastin-25
Roche, Luxembourg - Bevax
Elea, Argentina - Mvasi
Amgen, United States; Amgen Europe, Netherlands
Glossary
| Term | Definition |
|---|---|
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.